Top Midday Stories: DigitalBridge to Be Acquired by SoftBank; Ultragenyx's Brittle Bone Disease Drug Studies Miss Primary Endpoints

MT Newswires Live
2025/12/30

All three major US stock indexes were down in late-morning trading Monday to kick off the final few trading days of the year.

In company news, DigitalBridge (Group DBRG) has agreed to be acquired by SoftBank Group for about $4 billion, SoftBank said Monday. Under the terms of the deal, SoftBank will indirectly acquire all outstanding shares of DigitalBridge for $16 each in cash, representing a 15% premium over DigitalBridge's closing share price on Dec. 26. The deal is expected to close in H2 of 2026, the company said. DigitalBridge shares were up 9.6% around midday.

Ultragenyx Pharmaceutical (RARE) and its collaboration partner Mereo BioPharma (MREO) said Monday that phase 3 studies of setrusumab to treat Osteogenesis Imperfecta did not achieve the primary endpoints of reduction in annualized clinical fracture rate compared to a placebo or bisphosphonates. Ultragenyx shares were down 44.3%, while Mereo shares were off 90.5%.

Lululemon Athletica's (LULU) founder and major shareholder Chip Wilson said Monday he is nominating three independent director candidates for the company's board, to be voted on at the 2026 annual shareholders' meeting. Lululemon shares were up 0.7%.

Coupang (CPNG) said Monday it will start a 1.685 trillion won ($1.18 billion) compensation program following a recent personal data breach. Coupang shares were up 1.2%.

Energy Fuels (UUUU) said Monday it exceeded its previous guidance for finished uranium production, mined uranium ore production and uranium concentrate sales for 2025. Energy Fuels shares were up 6.3%.

Price: 15.27, Change: +1.35, Percent Change: +9.70

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10